Top

International Journal of Clinical Oncology

Published in:

01-04-2020 | Gastric Cancer | Original Article

Lack of association between interleukin-22 gene polymorphisms and cancer risk: a case–control study and a meta-analysis

Authors: Huan Wang, Chao Huang, Yuxiao Liu, Puyu Yang, Yuxiao Liao, Xiuli Gu, Xianhong Feng, Bifeng Chen

Published in: International Journal of Clinical Oncology | Issue 4/2020

Abstract

Background

Interleukin-22 (IL22) has been implicated in inflammation and tumorigenesis. The association between IL22 gene polymorphisms and cancer risk has been widely explored. However, the limited sample sizes of previous studies may produce inadequate statistical power and conflicting results, which calls for further investigations. In this study, we recruited a total of 1490 cancer patients (480 liver cancer patients, 550 lung cancer patients, and 460 gastric cancer patients) and 800 normal controls to explore the associations between IL22 gene polymorphisms (rs1179251, rs2227485, rs2227511, and rs2227473) and cancer risk.

Method

The genotyping was performed with polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) and Sanger sequencing.

Results

Our results showed that none of the four IL22 gene polymorphisms was associated with the risk of liver, lung or gastric cancer in Hubei Han Chinese population. To improve the statistical strength, a meta-analysis was further conducted. The results further confirmed our present findings and showed that rs1179251, rs2227485, and rs2227473 were not associated with cancer risk in total or stratified analysis.

Conclusion

Consequently, the rs1179251, rs2227485, rs2227511, and rs2227473 polymorphisms may not be associated with cancer risk. However, further investigations using larger samples in different ethnic populations are required.

Available only for authorised users

Lim C, Savan R (2014) The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev 25(3):257–271. https://doi.org/10.1016/j.cytogfr.2014.04.005 CrossRefPubMed

Wolk K, Sabat R (2006) Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 17(5):367–380. https://doi.org/10.1016/j.cytogfr.2006.09.001 CrossRefPubMed

Sabat R, Ouyang W, Wolk K (2014) Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 13(1):21–38. https://doi.org/10.1038/nrd4176 CrossRefPubMed

Wolk K, Witte E, Witte K et al (2010) Biology of interleukin-22. Semin Immunopathol 32(1):17–31. https://doi.org/10.1007/s00281-009-0188-x CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 CrossRefPubMed

Zhang M, Tuo J, Li GC (2013) Wei SZ (2018) Cancer incidence and mortality in Hubei cancer registries. Cancer Res Prev Treat 45(06):414–419. https://doi.org/10.3971/j.issn.1000-8578.2018.17.1200 CrossRef

Cardon LR, Bell JI (2001) Association study designs for complex diseases. Nat Rev Genet 2(2):91–99. https://doi.org/10.1038/35052543 CrossRefPubMed

Shastry BS (2009) SNPs: impact on gene function and phenotype. Methods Mol Biol 578:3–22. https://doi.org/10.1007/978-1-60327-411-1_1 CrossRefPubMed

Qin SY, Yang XW, Luo W et al (2015) Association of interleukin 22 polymorphisms with gastric cancer risk. Tumour Biol 36(3):2033–2039. https://doi.org/10.1007/s13277-014-2810-3 CrossRefPubMed

10.

He X, Wang XH, Qiu ZG et al (2013) A study on the correlation between single nucleotide polymorphism (SNP) of IL-22 gene and susceptibility to HCC. J Gannan Med Univ 33(1):29–32

11.

Wang YM, Li ZX, Tang FB et al (2016) Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population. Tumour Biol 37(2):2233–2242. https://doi.org/10.1007/s13277-015-4022-x CrossRefPubMed

12.

Thompson CL, Plummer SJ, Tucker TC et al (2010) Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 21(8):1165–1170. https://doi.org/10.1007/s10552-010-9542-5 CrossRefPubMed

13.

Mohebbi SR, Karimi K, Rostami F et al (2014) Association of interleukin-22 gene polymorphism (rs1179251) and colorectal cancer risk in the Iranian population. Indian J Virol 22(1):29–36. https://doi.org/10.1007/s13337-011-0029-0 CrossRef

14.

Zhao T, Wu X, Liu J (2015) Association between interleukin-22 genetic polymorphisms and bladder cancer risk. Clinics (Sao Paulo) 70(10):686–690. https://doi.org/10.6061/clinics/2015(10)05 CrossRef

15.

Liao F, Hsu YC, Kuo SH et al (2014) Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphoma. Blood Cancer J 4:e20. https://doi.org/10.1038/bcj.2014.70 CrossRef

16.

Eun YG, Shin IH, Lee YC et al (2013) Interleukin 22 polymorphisms and papillary thyroid cancer. J Endocrinol Invest 36(8):584–587. https://doi.org/10.3275/8879 CrossRefPubMed

17.

Zhang G, Chen X, Chan L et al (2011) An SNP selection strategy identified IL-22 associating with susceptibility to tuberculosis in Chinese. Sci Rep 1:20. https://doi.org/10.1038/srep00020 CrossRefPubMedPubMedCentral

18.

Munafò MR, Flint J (2004) Meta-analysis of genetic association studies. Trends Genet 20(9):439–444. https://doi.org/10.1016/j.tig.2004.06.014 CrossRefPubMed

19.

Chen BF, Yi C, Wang JD et al (2019) A comprehensive study of CD44 rs 187115 variant and cancer risk in a central Chinese population. J Cell Biochem 120(8):12949–12957. https://doi.org/10.1002/jcb.28566 CrossRefPubMed

20.

Sedgwick P (2012) Multiple significance tests: the Bonferroni correction. BMJ 344:e509. https://doi.org/10.1136/bmj.e509 CrossRef

21.

Hayashino Y, Noguchi Y, Fukui T (2005) Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 15(6):235–243CrossRefPubMedPubMedCentral

22.

Cargill M, Altshuler D, Ireland J et al (1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 22(3):231–238. https://doi.org/10.1038/10290 CrossRefPubMed

23.

Lek M, Karczewski KJ, Minikel EV et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536(7616):285–291. https://doi.org/10.1038/nature19057 CrossRefPubMedPubMedCentral

24.

Zeng Y, Wang G, Yang E et al (2015) Aberrant gene expression in humans. PLoS Genet 11(1):e1004942. https://doi.org/10.1371/journal.pgen.1004942 CrossRefPubMedPubMedCentral

25.

Zhang J, Zhao T, Xu C et al (2018) Four polymorphisms in the IL-22 gene and the risk of cancer: a meta-analysis. J Evid Based Med 11(2):101–104. https://doi.org/10.1111/jebm.12296 CrossRefPubMed

26.

Lin L, Xu W, Zhang G et al (2017) Association of interleukin-22 polymorphisms with the colon cancer: a case-control study. Immunol Lett 188:59–63. https://doi.org/10.1016/j.imlet.2017.06.007 CrossRefPubMed

27.

Hamed A, Gholamreza A, Ahmad J et al (2018) Atorvastatin, losartan and captopril may upregulate IL-22 in hypertension and coronary artery disease. Life Sci 207:525–531. https://doi.org/10.1016/j.lfs.2018.07.005 CrossRef

28.

Ding GG, Zhang GL, Chen XC et al (2012) A study on the relationship between single nucleotide polymorphisms of interleukin-22 and susceptibility to pulmonary tuberculosis. Chin J Tuberc Respir Dis 35(8):596–600

Title: Lack of association between interleukin-22 gene polymorphisms and cancer risk: a case–control study and a meta-analysis
Authors: Huan Wang
Chao Huang
Yuxiao Liu
Puyu Yang
Yuxiao Liao
Xiuli Gu
Xianhong Feng
Bifeng Chen
Publication date: 01-04-2020
Publisher: Springer Singapore
Keywords: Gastric Cancer
Gastric Cancer
Published in: International Journal of Clinical Oncology / Issue 4/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01595-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2020

A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study

Association of the primary tumor’s SUVmax with survival after surgery for clinical stage IA esophageal cancer: a single-center retrospective study

Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study

Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma

HPV vaccination in Japan: can educational intervention promote a father’s intention to encourage his daughter’s vaccination?

Correction to: Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer